Reagent sets and gene signatures for renal tubule injury

• US 7,588,892 B2
• Filed: 07/18/2005
• Issued: 09/15/2009
• Est. Priority Date: 07/19/2004
• Status: Expired due to Fees

• Current Assignee: US Department of Health and Human Services (Government of the United States of America)
• Original Assignee: Entelos, Inc. (SilkRoad Inc.)
• Inventors: Fielden, Mark, Kolaja, Kyle, Jarnagin, Kurt, Natsoulis, Georges
• Primary Examiner(s): Horlick; Kenneth R.
• Assistant Examiner(s): Babic; Christopher M.
• Application Number:
  US11/184,272
• Publication Number:
  US 20060057066A1
• Time in Patent Office: 1,520 Days
• Field of Search: None
• US Class Current: 435/6.14
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 2800/347 Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The invention discloses reagent sets and gene signatures for predicting onset of renal tubule injury in a subject. The invention also provides a necessary set of 186 genes useful for generating signatures of varying size and performance capable of predicting onset of renal tubule injury. The invention also provides methods, apparatuses and reagents useful for predicting future renal tubule injury based on expression levels of genes in the signatures. In one particular embodiment the invention provides a method for predict whether a compound will induce renal tubule injury using gene expression data from sub-acute treatments.

Claims

1. A method for testing whether a compound will induce renal tubule injury in a test subject, the method comprising:

a) administering a dose of compound to at least one test subject, wherein the test subject is a mouse or rat;

b) after a selected time period, obtaining a biological sample from the at least one test subject;

c) measuring the expression levels in the biological sample of at least a plurality of sequences selected from Table 4, wherein the plurality of sequences comprises AI105417, BF404557, U08257, BF285022, and AF155910 and has at least 2% of the total impact of all of the sequences in Table 4; and

d) determining whether the sample is in the positive class for renal tubule injury using a classifier comprising at least the plurality of sequences for which the expression levels are measured.

2. The method of claim 1, wherein the test compound is administered by route of IV, PO, or IP.

3. The method of claim 1, wherein the dose administered does not cause histological or clinical evidence of renal tubule injury at about 5 days.

4. The method of claim 1, wherein the biological sample comprises kidney tissue.

5. The method of claim 1, wherein the selected period of time is about 5 days or fewer.

6. The method of claim 1, wherein said selected period of time is at least 28 days.

7. The method of claim 1, wherein the expression levels are measured as log₁₀ ratios of a compound-treated biological sample to a compound-untreated biological sample.

8. The method of claim 1, wherein the classifier is a non-linear classifier.

9. The method of claim 1, wherein the classifier is a linear classifier.

10. The method of claim 9, wherein the linear classifier comprises the sequences and weights corresponding to any one of iterations 1 through 5 in Table 4.

11. The method of claim 10, wherein the linear classifier for renal tubule injury classifies the nephrotoxic versus non-nephrotoxic compounds listed in Table 2 with a training log odds ratio of greater than or equal to 4.35.

12. The method of claim 1, wherein the plurality of sequences from Table 4 includes at least 8 sequences selected having at least 4% of the total impact of all of the sequences in Table 4.